Should Tamoxifen Be Used in Breast Cancer Prevention?

[1]  A. Rademaker,et al.  Acceptance of tamoxifen chemoprevention by physicians and women at risk , 2004, Cancer.

[2]  Stephen W Duffy,et al.  A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.

[3]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[4]  S. Hulley,et al.  The WHI estrogen-alone trial--do things look any better? , 2004, JAMA.

[5]  Alberto Costa,et al.  Progress in chemoprevention of breast cancer. , 2004, Critical reviews in oncology/hematology.

[6]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer , 2003, Cancer.

[7]  J. Cuzick,et al.  Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Goss.  Breast cancer prevention—clinical trials strategies involving aromatase inhibitors , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  Valerie Beral,et al.  Breast cancer and hormone-replacement therapy in the Million Women Study , 2003, The Lancet.

[10]  A. Luini,et al.  A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. , 2003, Journal of the National Cancer Institute.

[11]  V. Vogel,et al.  Update on breast cancer prevention. , 2003, Oncology.

[12]  C. Hudis,et al.  Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Paik,et al.  Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. , 2003, Journal of the National Cancer Institute.

[14]  B. Weber,et al.  Application of breast cancer risk prediction models in clinical practice. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J Cuzick,et al.  Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.

[16]  P. Boyle,et al.  Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. , 2003, Journal of the National Cancer Institute.

[17]  M Baum,et al.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.

[18]  P. Boyle,et al.  Rationale for a study adding tamoxifen to HRT. , 2002, European journal of cancer.

[19]  W. Rubinstein,et al.  Mathematical modeling for breast cancer risk assessment. State of the art and role in medicine. , 2002, Oncology.

[20]  S. Cummings,et al.  American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[22]  U. P. S. T. Force,et al.  Chemoprevention of Breast Cancer: Recommendations and Rationale , 2002, Annals of Internal Medicine.

[23]  T. Walsh,et al.  Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. , 2001, JAMA.

[24]  M. Levine,et al.  Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[25]  D Spiegelman,et al.  Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. , 2001, Journal of the National Cancer Institute.

[26]  D. Wickerham,et al.  Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  K. Heimdal,et al.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study , 2000, The Lancet.

[28]  P. Goss,et al.  Breast cancer risk following irradiation for Hodgkin's disease. , 2000, Cancer treatment reviews.

[29]  P. Brown,et al.  Chemoprevention of breast cancer , 2000, Breast Cancer Research and Treatment.

[30]  M H Gail,et al.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.

[31]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[32]  J Benichou,et al.  Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.

[33]  J. Costantino,et al.  Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Frykberg.  Lobular Carcinoma In Situ of the Breast , 1999, The breast journal.

[35]  J. Sloane,et al.  Oestrogen receptor expression in the normal and pre‐cancerous breast , 1999, The Journal of pathology.

[36]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[37]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[38]  P. Boyle,et al.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.

[39]  T. Powles,et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.

[40]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[41]  H. Johansson,et al.  Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. , 1995, Journal of the National Cancer Institute.

[42]  M. Seller,et al.  Unusual case of Smith-Lemli-Opitz syndrome "type II". , 1995, American journal of medical genetics.

[43]  E. Lustbader,et al.  Validation of a breast cancer risk assessment model in women with a positive family history. , 1994, Journal of the National Cancer Institute.

[44]  D Spiegelman,et al.  Validation of the Gail et al. model for predicting individual breast cancer risk. , 1994, Journal of the National Cancer Institute.

[45]  N. Risch,et al.  Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994 .

[46]  V. Vogel.  Breast cancer risk: weaving facts into fabric , 1993, Breast cancer research and treatment.

[47]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[48]  S. Tretli.  Height and weight in relation to breast cancer morbidity and mortality. A prospective study of 570,000 women in Norway , 1989, International journal of cancer.

[49]  T. Powles,et al.  Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial , 2004, Breast Cancer Research and Treatment.

[50]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[51]  L. Newman,et al.  Breast cancer risk assessment models , 2003, Cancer.

[52]  U. Veronesi,et al.  HRT opposed to low-dose tamoxifen (HOT study): rationale and design. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[53]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[54]  J. Mackay.  IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-1) - a randomised prevention trial , 2002 .

[55]  A. Neugut,et al.  Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.